- Main
Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
- Zhang, Yajia;
- Pitchiaya, Sethuramasundaram;
- Cieślik, Marcin;
- Niknafs, Yashar S;
- Tien, Jean C-Y;
- Hosono, Yasuyuki;
- Iyer, Matthew K;
- Yazdani, Sahr;
- Subramaniam, Shruthi;
- Shukla, Sudhanshu K;
- Jiang, Xia;
- Wang, Lisha;
- Liu, Tzu-Ying;
- Uhl, Michael;
- Gawronski, Alexander R;
- Qiao, Yuanyuan;
- Xiao, Lanbo;
- Dhanasekaran, Saravana M;
- Juckette, Kristin M;
- Kunju, Lakshmi P;
- Cao, Xuhong;
- Patel, Utsav;
- Batish, Mona;
- Shukla, Girish C;
- Paulsen, Michelle T;
- Ljungman, Mats;
- Jiang, Hui;
- Mehra, Rohit;
- Backofen, Rolf;
- Sahinalp, Cenk S;
- Freier, Susan M;
- Watt, Andrew T;
- Guo, Shuling;
- Wei, John T;
- Feng, Felix Y;
- Malik, Rohit;
- Chinnaiyan, Arul M
- et al.
Published Web Location
https://doi.org/10.1038/s41588-018-0120-1Abstract
The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-